Asciminib May Be an “Attractive” Option in Newly Diagnosed CML Populations
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Sacituzumab Govitecan Yields Response But Questions Remain on Usefulness in Bladder Cancer
Adjuvant sacituzumab govitecan demonstrated a complete response, but its future in bladder cancer is uncertain after a recent protocol amendment.
DFF332 Shows Potential Activity in Advanced Clear Cell RCC
Treatment with DFF332 appears to be safe and tolerable across all dose levels, according to Sumanta Kumar Pal, MD.
Avelumab Plus Chemo Improved Survival in Muscle-Invasive Urothelial Carcinoma
Neoadjuvant avelumab plus cisplatin yielded high event-free survival in muscle-invasive urothelial carcinoma.
Subcutaneous Amivantamab Yields Improves Response Vs IV in EGFR-Mutated NSCLC
Subcutaneous amivantamab proved noninferior vs intravenous administration in EGFR-mutated non–small cell lung cancer.
Encorafenib Regimen Shows No PFS Improvement in Metastatic BRAF+ Melanoma
Subgroup findings suggest a PFS benefit with the addition of encorafenib/binimetinib in patients with liver metastases.
PFS Increase Noted in Amivantimab Combo in High-RISK EGFR-Mutant NSCLC
Updated MARIPOSA results found improves progression-free survival in patients with high-risk EGFR-mutant advanced non-small cell lung cancer when treated with amivantimab/lazertinib.
Brentuximab Vedotin Improves Efficacy in Classical Hodgkin Lymphoma
Brentuximab vedotin led to unprecedented progression-free survival for patients with classical Hodgkin lymphoma.
Pelapresib/Ruxolitinib Reduces Spelonomegaly in MPN
A reduction in splenomegaly was observed when the combination of pelabresib plus ruxolitinib was used to treat patients with myelofibrosis.
Post-Hoc OPTIC Results Showcase Continued Safety in CP-CML
Ponatinib remains a safe treatment for patients with chronic-phase chronic myeloid leukemia.
Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma
Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.
Expert Highlights Potential Utility of Amivantamab in Advanced EGFR+ NSCLC
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
Artificial Intelligence Tool May Improve Oncology Multi-Trial Matching
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
FDA Acknowledges Zolbetuximab BLA Resubmission for CLDN18.2+ Gastric Cancer
The FDA has set a new Prescription Drug User Fee Act date of November 9, 2024, for zolbetuximab in this gastric cancer population.
41 A Case Series of Sarcomas
Asciminib Improves Efficacy Vs TKIs in Ph+ Chronic Myeloid Leukemia
The benefit-risk profile of asciminib may change the chronic myeloid leukemia treatment paradigm, according to Jorge E. Cortes, MD.
Lorlatinib Boosts Progression-Free Survival in ALK+ NSCLC
Lorlatinib may show “unprecedented” improvements in outcomes for those with advanced ALK-positive NSCLC, according to Benjamin J. Solomon, MBBS, PhD.
Nivolumab Combo Receives European Approval in Advanced Urothelial Carcinoma
The CheckMate -901 trial led to the approval of the nivolumab combination for unresectable or metastatic urothelial carcinoma in the European Union.
Comparative Efficacy of PTCY and ATG in GvHD Prophylaxis: Insights from Mismatched and Matched Donor Transplant Studies
Efficacy of post-transplant cyclophosphamide vs antithymocyte globulin remains a large discussion for patients with graft-vs-host disease.
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
ASTCT discusses Richter transformation and treatment options available for this population.
Nivolumab/Ipilimumab Yields Sustained Responses in Advanced HCC
The 5-year follow-up results from CheckMate 040 showed consistent responses with nivolumab/ipilimumab in advanced hepatocellular carcinoma.
FDA Approves Liso-cel in Relapsed/Refractory Mantle Cell Lymphoma
Findings from the TRANSCEND NHL 001 trial support the FDA approval of lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma.
Zanidatamab Earns FDA Priority Review in HER2+ Biliary Tract Cancer
The FDA has set a Prescription Drug User Fee Act date of November 29, 2024, for zanidatamab in this biliary tract cancer population.
Developing a Passion for Treating and Advancing Breast Cancer Care
Tiffany A. Traina, MD, FASCO, and Sherry Shen, MD, share their personal and professional journeys to becoming breast oncologists at Memorial Sloan Kettering Cancer Center.
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
FDA Grants Priority Review to Inavolisib in HR+/HER2– PIK3CA+ Breast Cancer
The FDA has set a Prescription Drug User Fee Act date of November 27, 2024, for the inavolisib-based combination in this breast cancer population.
Selpercatinib Earns Accelerated Approval in Pediatric RET+ Thyroid Cancer
Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
AFM24/Atezolizumab Earns FDA Fast Track Status in EGFR Wild-Type NSCLC
Data from the phase 1/2a AFM24-102 trial support the fast track designation for the AFM24 combination in EGFR wild-type non–small cell lung cancer.
Achieving Precision With Radiation Oncology Advancements in NSCLC
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction